BDO Biotech Brief | Winter 2022

NASDAQ Biotech Index falls flat despite minting more than 100 new firms

Despite adding almost 130 new companies, continued investment into biotech in the private markets, and research into breakthrough medicines, the NASDAQ Biotech Index (NBI) closed out 2021 practically flat, as prices continued to drop in Q1 2022. Read our latest analysis of the NBI and biotech industry to see what is behind the NBI performance and what this means for the industry in 2022.

Issue Topics

M&A Momentum Continues

Small and mid-cap firms lagged behind their larger peers

M&A Momentum Continues

For companies on the NBI, research focus areas include gene therapy, mRNA and small molecule drugs

M&A Momentum Continues

Available cash increased, creating a friendly environment for dealmaking

Read Report